pioneer 9 semaglutide Dose-response, efficacy, and safety of oral monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial Summary of PIONEER 1-8 study

The study indicates that combining semaglutide with trevogrumab (anti-GDF8/anti-myostatin) helped prevent about half of the lean mass loss typically associated with GLP-1 therapy, while increasing fat loss

PlexusDx explains why monotherapy is standard and how genetic testing helps identify your ideal single-agent approach

Our New York medical weight loss treatment is personalized, evidence-based, and 100% online

Step 1: Slide to Open

Background The Enhanced Games (TEG) initiativean event that permits the off-label use of FDA-approved drugs for performance enhancement under medical supervisionrepresents a revolutionary yet highly controversial disruption in modern sport